Actimed plans trials to treat muscle wasting syndrome in cancer patients
The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.
The company aims to start two trials in H1 2024 based on its current timeline, depending on if it closes its Series B round soon.
What's Your Reaction?
